AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, covers production of five biopharmaceutical products with at least 35 batches annually, supporting global supply chain reliability. The agreement includes process transfer, scale-up, regulatory validation, and commercial production to meet approvals from EMA, FDA, MHRA, and PMDA. The Yokohama site, opening in 2027, will enhance AGC's global single-use bioproduction capacity and strengthen Japan's strategic role in resilient biopharma supply chains amid geopolitical risks.
AGC Biologics has signed a multi-year commercial manufacturing contract valued at hundreds of millions of dollars with a major biopharma company for its new Yokohama facility. The contract covers production of five biopharmaceutical programs, securin...
AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Replimune Group's stock fell sharply by 38.01% following FDA briefing documents that deemed its skin cancer drug trial data "not interpretable," signaling a major regulatory setback. Other companies like Travelzoo and Amkor Technology also saw signif...
Polaris Inc. reported a strong quarterly performance with earnings per share of $1.97, beating estimates by over 155%, and revenues of $2.02 billion, up 9.2% year-over-year. The growth was driven by sales recovery in the utility off-road vehicle segm...
